Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) had its target price boosted by Canaccord Genuity from $33.00 to $38.00 in a research report report published on Thursday morning. The firm currently has a hold rating on the stock.

Other analysts also recently issued reports about the company. Royal Bank Of Canada set a $58.00 target price on Pacira Pharmaceuticals and gave the company a buy rating in a research report on Sunday, July 30th. Mizuho reiterated a buy rating and set a $54.00 target price on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 26th. HC Wainwright set a $59.00 target price on Pacira Pharmaceuticals and gave the company a buy rating in a research report on Thursday, August 3rd. Needham & Company LLC initiated coverage on Pacira Pharmaceuticals in a research report on Tuesday, August 22nd. They set a buy rating and a $55.00 target price for the company. Finally, Jefferies Group LLC reiterated a buy rating and set a $59.00 target price on shares of Pacira Pharmaceuticals in a research report on Thursday, September 7th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $49.71.

Pacira Pharmaceuticals (NASDAQ:PCRX) traded up $1.90 during trading hours on Thursday, hitting $42.05. The stock had a trading volume of 787,300 shares, compared to its average volume of 927,270. The company has a quick ratio of 7.26, a current ratio of 6.99 and a debt-to-equity ratio of 1.03. Pacira Pharmaceuticals has a 1 year low of $29.81 and a 1 year high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.15. The firm had revenue of $67.30 million during the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.20 EPS. research analysts expect that Pacira Pharmaceuticals will post -0.96 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/12/canaccord-genuity-boosts-pacira-pharmaceuticals-inc-pcrx-price-target-to-38-00.html.

In other Pacira Pharmaceuticals news, Director Paul J. Hastings sold 1,044 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total value of $37,740.60. Following the completion of the transaction, the director now owns 3,518 shares of the company’s stock, valued at approximately $127,175.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Kristen Marie Williams sold 3,461 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the completion of the transaction, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at approximately $783,216. The disclosure for this sale can be found here. In the last ninety days, insiders sold 33,390 shares of company stock valued at $1,215,480. Insiders own 6.60% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. increased its stake in shares of Pacira Pharmaceuticals by 9.2% in the second quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock valued at $165,914,000 after buying an additional 294,494 shares during the period. Vanguard Group Inc. increased its stake in shares of Pacira Pharmaceuticals by 7.4% in the second quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock valued at $146,538,000 after buying an additional 211,982 shares during the period. HealthCor Management L.P. increased its stake in shares of Pacira Pharmaceuticals by 63.1% in the second quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock valued at $85,564,000 after buying an additional 693,799 shares during the period. Macquarie Group Ltd. increased its stake in shares of Pacira Pharmaceuticals by 5.8% in the third quarter. Macquarie Group Ltd. now owns 1,154,545 shares of the company’s stock valued at $43,353,000 after buying an additional 63,015 shares during the period. Finally, State Street Corp increased its stake in shares of Pacira Pharmaceuticals by 1.0% in the second quarter. State Street Corp now owns 1,118,083 shares of the company’s stock valued at $53,340,000 after buying an additional 10,727 shares during the period.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.